glp-1 atrial fibrillation Impact of Receptor Agonist Therapy on Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis Glucagon-Like Peptide-1 Protects Against Atrial

Combination users were matched, in a 1:1 ratio, to patients prescribed the same background drug, duration of background drug, and time conditional propensity score

Bridging the gap between guidelines and practice will require systemic interventions, including physician training, patient-centered care models, and devising research strategies such as national HF registries to understand and tailor therapeutic approaches from an Indian perspective.

Macros are estimates and may vary based on ingredients used

Conclusions GLP-1RAs had a neutral effect on the composite cardiovascular outcomes but reduced composite kidney events in the patients with advanced DKD compared with DPP-4is.

Evaluate the benefits and concerns surrounding GLP-1 treatments